FXYD1: A Drug Target / Disease Biomarker (G5348)

Target Name: FXYD1

NCBI ID: G5348

FXYD1

FXYD1: A Drug Target / Disease Biomarker

FXYD1, also known as fasorfinidase alpha, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the fasorinidase family, which is involved in the processing of fasorinides, a type of lipid molecule that is derived from arachidonic acid. FXYD1 is also known as a drug target and has been identified as a potential biomarker for various diseases, including cancer.

FXYD1 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, liver, and pancreas. It is primarily localized to the endoplasmic reticulum (ER), where it is involved in the processing of fasorinides. Fasorinides are derived from arachidonic acid, which is a fatty acid that is synthesized in the body and is found in various foods, including meat, dairy, and eggs.

FXYD1 is a critical enzyme for the synthesis of fasorinides, which are involved in various physiological processes in the body. For example, fasorinides are involved in the production of various signaling molecules, including inflammatory compounds and vasodilators. They are also involved in the regulation of cellular signaling pathways, including the TGF-beta pathway.

FXYD1 has also been identified as a potential drug target for various diseases. For example, FXYD1 has been shown to be involved in the development and progression of cancer. Studies have shown that high levels of FXYD1 are associated with poor prognosis in cancer patients. Additionally, FXYD1 has been shown to be involved in the regulation of cell death, which is a critical process that is involved in the regulation of many cellular processes.

FXYD1 has also been identified as a potential biomarker for various diseases, including cancer. Studies have shown that FXYD1 is downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, FXYD1 has been shown to be involved in the regulation of cellular signaling pathways, which are critical for the development and progression of cancer.

In conclusion, FXYD1 is a protein that is expressed in various tissues throughout the body and is involved in the processing of fasorinides. It is also a key enzyme in the fasorinide synthesis and has been identified as a potential drug target and biomarker for various diseases, including cancer. Further research is needed to fully understand the role of FXYD1 in various cellular processes and its potential as a therapeutic target.

Protein Name: FXYD Domain Containing Ion Transport Regulator 1

Functions: Associates with and regulates the activity of the sodium/potassium-transporting ATPase (NKA) which transports Na(+) out of the cell and K(+) into the cell. Inhibits NKA activity in its unphosphorylated state and stimulates activity when phosphorylated. Reduces glutathionylation of the NKA beta-1 subunit ATP1B1, thus reversing glutathionylation-mediated inhibition of ATP1B1. Contributes to female sexual development by maintaining the excitability of neurons which secrete gonadotropin-releasing hormone

The "FXYD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FXYD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets